Chandana Shekar, MD
Cardiovascular Disease · Pocatello, IDNPI 1891102414
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $247, more than ten times the $20 reported in 2021. That places this record below the midpoint for cardiovascular disease clinicians in ID, where the typical reported total is $1,233.
Across 30 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$86
- Merck$62
- E.r. Squibb & Sons, L.L.C.$59
- Boehringer Ingelheim$59
- Pfizer$49
- Amgen$41
- plus $217 from 7 others
What the payments were for
- Food & beverage$573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $86 |
| Merck | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Boehringer Ingelheim | 3 | $59 |
| Pfizer | 3 | $49 |
| Amgen | 2 | $41 |
| Abbott | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Boston Scientific | 2 | $36 |
| Bridgebio Pharma, Inc. | 1 | $30 |
| AstraZeneca | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Getinge USA Sales, LLC | 1 | $20 |
How this compares
$573 in reported general payments places this provider in the 25th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $47,489 |
| FarxigaDapagliflozin Propanediol | 53 | $44,746 |
| EntrestoSacubitril/Valsartan | 52 | $33,792 |
| JardianceEmpagliflozin | 42 | $32,273 |
| Repatha SureclickEvolocumab | 50 | $29,249 |
| XareltoRivaroxaban | 15 | $20,850 |
| VascepaIcosapent Ethyl | 21 | $13,372 |
| Metoprolol Succinate | 351 | $3,171 |
| Atorvastatin Calcium | 333 | $2,436 |
| Ranolazine ErRanolazine | 17 | $1,768 |
| Potassium Chloride | 57 | $1,403 |
| Rosuvastatin Calcium | 151 | $1,324 |
| Nitroglycerin | 75 | $1,207 |
| Ezetimibe | 119 | $1,063 |
| Carvedilol | 124 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $47,48952 claims |
| AstraZenecaFarxiga | $29 | $44,74653 claims |
| NovartisEntresto | $86 | $33,79252 claims |
| Boehringer IngelheimJardiance | $59 | $32,27342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 59 cardiovascular disease providers in Idaho.
Other cardiovascular disease in Pocatello
- Jacob DelarosaPocatello$226K
- Ryan LongmorePocatello$60K
- Benjamin CallPocatello$5K
- Fernando GrigeraPocatello$4K
- Jarrah AlfadhliPocatello$899
- David HinchmanBoise$324K
- David LaxsonKetchum$135K
- Robyn BrydeBoise$27K
- Ronald FritzCoeur D Alene$17K
- Douglas BlankIdaho Falls$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.